Parkinson Disease

Mike Hooven, chairman and CEO of Enable Injections, and Randall Moreadith, MD, PhD, chief development officer of Serina Therapeutics, provided insight on the development plans of SER-252, an investigational apomorphine therapy for advanced Parkinson disease.

The lead neuroscientist and lead data scientist at Rune Labs talked about leveraging mobility data to monitor progression in patients with Parkinson disease. [WATCH TIME: 7 minutes]

Khashayar Dashtipour, MD, PhD, an associate professor of neurology at the Loma Linda University Health System, provided an overview of an upcoming CME-credited educational course on movement disorders scheduled for June 1st in Minnetonka, Minnesota.

The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]

The professor of neurological surgery at Weill Cornell medicine talked about the regulatory hurdles and challenges in patient selection and delivery methods for gene therapy in Parkinson disease. [WATCH TIME: 5 minutes]

In a recent study assessing basal ganglia activity during REM sleep, results revealed that elevated beta power may be correlated with the severity of REM sleep behavior disorder in Parkinson disease.

Depression prior to PD diagnosis predicts increased dementia risk and mortality, emphasizing its significance in disease progression.

Clinical trials assessing cell therapies for Parkinson disease treatment may show early potential in improving both motor and nonmotor symptoms.

Kremens gave closing thoughts on the promise of the Parkinson disease research field, the outlook of drug development, and what clinicians should be excited for next.

Daniel Kremens, MD, JD, described positive 18-month data on bemdaneprocel, an investigational cell-based approach for patients with Parkinson disease.

The director for the Gene Therapy Institute at The Ohio State University talked about the latest developments in gene therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]

ASPIRO, an open-label trial, will assess the safety and tolerability of ANPD001, an investigational autologous neuronal replacement therapy being studied as a regenerative therapy for PD.

Neurology News Network. for the week ending May 4, 2024. [WATCH TIME: 3 minutes]

The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Disease. [WATCH TIME: 6 minutes]

In this segment, Kremens described pump therapies currently in development, such as ND0612 and ABBV-951.

Kremens gave thoughts on the use of several investigational continuous agents, including IPX203, risvodetinib, and P2B001.

As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.

Neurology News Network. for the week ending April 27, 2024. [WATCH TIME: 3 minutes]

In this conversation, Kremens discussed the common use of antiemetics in Parkinson disease, the real-world data surrounding these agents, and whether there are certain clinical advantages to apomorphine hydrochloride injection.

A recent study showed the relationship between genes associated with lysosomal function and environmental exposure to pesticides in Parkinson disease.

Daniel Kremens, MD, JD, provided commentary on a number of various amantadine formulations for Parkinson disease, and how timing of dosing impacts efficacy.

Kenneth Ngo, MD, medical director for the Brain Injury Program at Brooks Rehabilitation’s 3 inpatient hospitals, highlighted how cotreatment between music therapy and physical therapy can significantly improve the overall quality of life for patients with Parkinson disease.

Using the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score, SAGE-718 failed to distinguish itself from placebo.

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

Larry Gifford, a patient living with Parkinson Disease and president of the PD Avengers, discussed sleep issues and nighttime symptoms faced by millions of patients with the disease worldwide.

Tavapadon's phase 3 success complements ongoing monotherapy trials, addressing the need for effective and well-tolerated PD therapies.

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.

Neal K. Shah, CEO of CareYaya Health Technologies, an AI innovator in neurological care, discussed how technology is poised to transform the fight against Parkinson, with the potential to improve millions of lives and advance health equity.

Even at the highest modal dose range, findings from the phase 3 RISE-PD trial showed that IPX203 did not increase safety risks for patients with Parkinson disease over time.

The professor of neurology at University of Rochester discussed a new model on how Parkinson disease may originate, highlighting potential environmental causes and progression. [WATCH TIME: 5 minutes]